We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Drugs for Macular Degeneration—Reply

Jonathan Silver, MD, MBA1
[+] Author Affiliations
1George Washington University, Washington, DC
JAMA. 2014;312(19):2045. doi:10.1001/jama.2014.12748.
Text Size: A A A
Published online


In Reply Dr Stoilov and colleagues point out an inaccuracy in my Viewpoint: ranibizumab is not just the Fab portion of bevacizumab but rather a genetically engineered variant Fab fragment with several amino acid changes that increase binding affinity to VEGF. A correction accompanies this letter.

The implication is that these molecular differences justify the 100-fold higher price per milligram of ranibizumab vs bevacizumab. From a consumer point of view, higher price could be justified by some combination of product advantages and increased manufacturing cost. However, many experts believe there is no clinically significant advantage to ranibizumab1 and its manufacturing cost is likely to be lower because it is made in bacteria, whereas bevacizumab is made in mammalian cells.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview




July 2, 2014
Jonathan Silver, MD, MBA
1George Washington University, Washington, DC
JAMA. 2014;312(1):23-24. doi:10.1001/jama.2014.6672.
November 19, 2014
Ivaylo Stoilov, MD; Anne E. Fung, MD; Roman G. Rubio, MD
1Department of Ophthalmology, Genentech Inc, South San Francisco, California
JAMA. 2014;312(19):2044-2045. doi:10.1001/jama.2014.12741.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...